Article
Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.
Molecular oncology - 1 Apr 2020
Zang Hongjing, Qian Guoqing, Arbiser Jack, Owonikoko Taofeek K, Ramalingam Suresh S, Fan Songqing, Sun Shi-Yong
Abstract excerpt
The development of acquired resistance to osimertinib (Osim) (AZD9291 or TAGRISSOTM ), an FDA-approved third-generation epidermal growth factor receptor (EGFR) inhibitor for the treatment of EGFR-mutant nonsmall cell lung cancer (NSCLC), limits the long-term benefits for patients. Thus, effective treatment options are urgently needed. To this end, we explored whether honokiol (HNK), a natural product with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.